![]() ![]() Due to too few events, it was not possible to estimate VE for hospitalization and death. Waning immunity following vaccination was observed and was most pronounced during the Omicron period. VE against reinfection following any COVID-19 vaccine type administered in Denmark, peaked at 71% (95% CI: -Inf to 100%) at 104 days or more after vaccination during the Alpha period, 94% (95% CI: 92% to 96%) 14 to 43 days after vaccination during the Delta period, and 60% (95% CI: 58% to 62%) 14 to 43 days after vaccination during the Omicron period. Of these, 40,281 individuals had completed their primary vaccination series during the Alpha period (19.2%), 190,026 during the Delta period (64.9%), and 158,563 during the Omicron period (64.6%). The study population comprised of 209,814 individuals infected before or during the Alpha period, 292,978 before or during the Delta period, and 245,530 before or during the Omicron period. In total, 148,527 person-years and 44,192 SARS-CoV-2 infections were included for the analysis regarding reinfections. The VE estimates were calculated separately for three periods with different dominant SARS-CoV-2 variants (Alpha (B.1.1.7), Delta (B.1.617.2), or Omicron (B.1.1.529)) and by time since vaccination using unvaccinated as the reference. Estimates of VE against SARS-CoV-2 reinfection with 95% confidence intervals (CIs) were calculated using a Poisson regression model and adjusted for age, sex, country of origin, comorbidity, staying at hospital, calendar time, and test incidence using a Cox regression model. The study population included were individuals with prior SARS-CoV-2 infection. Using Danish nationwide registries, we obtained information on SARS-CoV-2 infections, COVID-19 vaccination, age, sex, comorbidity, staying at hospital, and country of origin. Prior Omicron infection protects against BA.4 and BA.5 variants.This study used a nationwide cohort design including all individuals with a confirmed SARS-CoV-2 infection, who were alive, and residing in Denmark between 1 January 2020 and 31 January 2022. Covid-19: Omicron infection is poor booster to immunity, study finds. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Omicron infection enhances Delta antibody immunity in vaccinated persons. Isolation and precautions for people with COVID-19. ![]() Is my upset stomach a symptom of Omicron?Ĭenters for Disease Control and Prevention. Decreasing incidence of chemosensory changes by COVID-19 variant. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-COV-2 during periods of Omicron and Delta variant dominance: A prospective observational study from the ZOE COVID Study. At-Home COVID-19 antigen tests-Take steps to reduce your risk of false negative: FDA safety communication.ĬDC COVID-19 Response Team. doi: 10.15585/mmwr.mm705152e3.Ĭenters for Disease Control and Prevention. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) variant cluster - Nebraska, November–December 2021. Awareness of SARS-CoV-2 Omicron variant infection among adults with recent COVID-19 seropositivity. COVID data tracker.Ĭenters for Disease Control and Prevention. ![]() Centers for Disease Control and Prevention. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |